Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Ocrelizumab by F. Hoffmann-La Roche for Autoimmune Encephalitis (Post-Infectious): Likelihood of Approval
Ocrelizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Autoimmune Encephalitis (Post-Infectious). According to...
Data Insights
Ocrelizumab by F. Hoffmann-La Roche for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
Ocrelizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Relapsing Remitting Multiple Sclerosis (RRMS)....